A tiny shift in price can boost profits more than a big jump in sales—yet most companies still set prices by “cost plus a bit.” In this episode, we drop into two boardrooms: one obsessed with costs, one obsessed with value—and only one survives the next price war.
McKinsey once showed that a 1% price move can swing profit by 6–8%—yet most teams still debate pennies on cost while ignoring dollars in perceived value. In this episode, we zoom in on the *choice* behind every price: are you anchoring on what it costs you to make, or on what it’s worth to the customer?
Think of two product managers launching nearly identical tools. One opens a spreadsheet, adds a safe markup, and calls it a day. The other sits with sales, studies win–loss deals, and asks customers what outcomes actually matter. Same product, completely different ceiling on what either can ever charge.
We’ll look at when each mindset protects you, when it quietly caps your upside, and how leading companies blend them without drifting into chaos or guesswork.
Some teams quietly let their spreadsheets decide prices; others treat pricing like product design, with hypotheses, tests, and iterations. That’s the real fork in the road. You’re not just choosing between “safe markup” and “aspirational value”—you’re choosing how much uncertainty you’re willing to manage in exchange for upside. In many markets, your buyers are doing their own math: benchmarking competitors, weighing switching costs, and calculating risk. Your job is to decide whose math you’ll respect first: your finance team’s, your customers’, or your competitors’—and how consciously you’ll mix them.
McKinsey claims a 1% price move can shift profit by up to 8%, yet 58% of manufacturers still default to cost-plus. That’s not because they’re irrational; it’s because cost data feels concrete, and “value” feels negotiable and political.
Behind the scenes, the real split isn’t just cost-first vs value-first—it’s *who* gets to be wrong. With cost-plus, if margins disappoint, you can blame the market: “We covered costs; demand just softened.” With value-led pricing, you’re implicitly betting that your understanding of customers is sharp enough to defend a bolder number—and if you miss, the forecast is on *you*.
So teams quietly bias toward the method that is easiest to defend in a meeting, not the one that best matches their market. That’s how industrial suppliers selling clear ROI still peg prices to input costs, while SaaS firms with weak differentiation overreach on value stories and stall growth.
A more pragmatic way to choose is to start from *risk profile* instead of philosophy. Ask:
- How visible and volatile are my costs? If input prices swing weekly, a rigid markup can lock you into bad deals; you may need prices that flex with customer outcomes or indexes. - How visible is my impact? If you can credibly show, “This saves you $500k a year in scrap,” anchoring on that impact is safer than pretending you’re a commodity. - How concentrated is my customer base? Selling to three giant buyers who negotiate hard makes sloppy value claims dangerous—but it also makes lazy markups easy to reverse-engineer and squeeze.
In tech and pharma, where differentiation is real but hard to quantify, leading teams treat willingness to pay like a variable to be modeled, not guessed. They run structured experiments: multiple packaging options, controlled price tiers, win–loss interviews focused on tradeoffs. HubSpot’s shift to value metrics didn’t come from one brainstorm—it came from tracking which feature customers *actually* treated as the heartbeat of the product and pricing around that.
The discipline here is to let *evidence* decide your bias: when data is rich on customer impact, tilt harder toward value; when it’s thin, use cost as a floor, not a ceiling.
A useful way to stress‑test your approach is to look at how pricing behaves under pressure. Think about three moments: launch, renewal, and crisis.
At launch, a hardware supplier might anchor on internal build sheets, then quietly add a “market stretch” line item based on comparable solutions. A year later at renewal, those same numbers often flip: the buyer leans on alternative quotes, and suddenly your narrative about uptime, fewer defects, or faster setup becomes the only defense against an automatic discount.
Now add crisis: input costs spike or demand drops. The firms that survive don’t cling to one doctrine; they know exactly which parts of their catalog can sustain bolder adjustments and which SKUs must track industry indexes to stay credible.
In medicine, this is like differentiating between routine generics and breakthrough therapies: one is reimbursed by formula, the other by documented outcomes and negotiated evidence.
Your own product line almost certainly has both hiding in plain sight.
AI will quietly turn pricing into a living system, updating like a weather forecast instead of a yearly budget. Algorithms will watch usage, churn risk, and even carbon intensity, then nudge prices or bonuses in real time. Your edge won’t be the math—everyone will have similar tools—but the rules you encode: which customers you protect, which behaviors you reward, and how clearly you narrate the “why” before regulators or buyers assume the worst.
Treat pricing less like carving numbers in stone and more like tending a garden: prune offerings that always get discounted, fertilize those buyers defend without blinking, and watch how “weather” like regulation or new entrants shifts growth. Your challenge this week: flag one offer to test a bolder price story—and one to strip back to essentials.
